Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals — Q1 2016 Earnings Presentation

23 slides from Keryx Biopharmaceuticals's earnings presentation, Apr 28, 2016

  1. Slide 1: First Quarter 2016 Financial Results

    First Quarter 2016 Financial Results April 28, 2016 Keryx Biopharmaceuticals, Inc. Exhibit 99.2

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures To supplement the financial measures presented in our press release and related conference call, and in accordance with accounting principles generally accepted in the United States (“GAAP”), Keryx also presents expected cash operating expenses in the 2016 financial guida

  4. Slide 4: First Quarter 2016 Financial Results – Agenda

    First Quarter 2016 Financial Results – Agenda Topic Speaker Introduction Amy Sullivan, VP, Corporate Development Strategy, Priorities and Commercial Update Greg Madison, Chief Executive Officer 1Q 2016 Results & Guidance Scott Holmes, Chief Financial Officer IDA NDD-CKD John Neylan, M.D., Chief Medi

  5. Slide 5: Building a Foundation for Long-Term Growth

    Building a Foundation for Long-Term Growth SOLID FUNDAMENTALS ESTABLISHED 2015 2017 POTENTIAL IDA APPROVAL 2016 DRIVE DIALYSIS ADOPTION AURYXIA: A NEW TREATMENT CATEGORY Leverage field team expansion Increase utilization Increase breadth & depth of prescribing Generate further data to support differ

  6. Slide 6: First Quarter 2016 Business Highlights

    First Quarter 2016 Business Highlights Expanded field based team fully trained and calling on treating community Auryxia net U.S. product sales of $5.6MM Announced positive top-line results from pivotal phase 3 trial for the treatment of iron deficiency anemia in non-dialysis dependent CKD patients

  7. Slide 7: Prescription Volume Increased ~17% from 4Q 2015 to 1Q 2016

    Source: IMS NPA, DaVita and Fresenius Prescription Volume Increased ~17% from 4Q 2015 to 1Q 2016 ~9,150 Auryxia prescriptions in 1Q 2016 43% of Auryxia prescriptions in 1Q 2016 not captured by IMS Volume growth driven by increased breadth and depth of prescribing Increased new writers: Cumulative ta

  8. Slide 8: Solid Fundamentals to Support Future Dialysis Growth

    Solid Fundamentals to Support Future Dialysis Growth Physician Payer Patient Increased breadth and depth of adoption Expanded field base team fully trained Majority of phosphate binder patients have unrestricted access ~70% of claims paid at the pharmacy ~74% of co-pays <$10 Patient persistency at ~

  9. Slide 9: Financial Highlights

    Financial Highlights Scott Holmes Chief Financial Officer

  10. Slide 10: First Quarter 2016 Financial Highlights

    First Quarter 2016 Financial Highlights ($ in thousands) Three Months Ended March 31, 2016 (unaudited) Three Months Ended March 31, 2015 (unaudited) Auryxia Net U.S. Product Sales $5,616 $422 License Revenue $1,209 $753 Total Revenue $6,825 $1,175 Cost of Goods Sold $1,071 $76 SG&A Expense $20,809 $

  11. Slide 11: Reconciliation of Total Operating Expenses to Cash Operating Expenses (Non-GAAP)

    Reconciliation of Total Operating Expenses to Cash Operating Expenses (Non-GAAP) ($ in thousands) Three Months Ended March 31, 2016 (unaudited) Three Months Ended March 31, 2015 (unaudited) SG&A Expense $20,809 $18,880 R&D Expense $7,616 $9,591 Total Operating Expenses* $28,425 $28,471 Less: non-cas

  12. Slide 12: 2016 Financial Guidance

    2016 Financial Guidance $ in millions FY 2016 Guidance Auryxia Net U.S. Product Sales* $31MM - $34MM Cash Operating Expenses $87MM - $92MM* Notes: * 2016 Cash Operating Expenses excludes; non-cash stock compensation expenses, non-cash commercial expenses and non-cash depreciation/amortization

  13. Slide 13: NDD CKD - Iron Deficiency Anemia Label Expansion Opportunity

    NDD CKD - Iron Deficiency Anemia Label Expansion Opportunity John Neylan, M.D. Chief Medical Officer

  14. Slide 14: Potential to Treat IDA in NDD-CKD Represents a Practice-Changing Opportunity

    Potential to Treat Iron Deficiency Anemia in Non-Dialysis Dependent CKD Represents a Practice-Changing Opportunity Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Na

  15. Slide 15: Progression of Chronic Kidney Disease

    Progression of Chronic Kidney Disease Progressing patients typically referred to nephrologist Prepare for renal replacement therapy Patients initiate dialysis GFR (mL/min) Often not diagnosed Patients typically under care of PCP Moderate to severe loss of kidney function Severe loss of kidney functi

  16. Slide 16: Baseline Laboratory Characteristics (ITT Population)

    Baseline Laboratory Characteristics (ITT Population) Mean Baseline Laboratory Values Ferric Citrate (N=117) Placebo (N=115) Hemoglobin (g/dL) 10.4 10.4 TSAT (%) 20.2 19.6 Ferritin (ng/mL) 85.9 81.7 Serum phosphorus (mg/dL) 4.2 4.1 Keryx Biopharmaceuticals Announces Positive Top-line Results from Piv

  17. Slide 17: Phase 3 Efficacy Endpoints

    *Sustained treatment effect on Hgb was defined as a mean change from baseline ≥0.75 g/dL over any 4-week time period during the 16-week, randomized efficacy period, provided that an increase of at least 1.0 g/dL had occurred during that 4-week period. Randomized Efficacy Period (16 Weeks) Ferric Cit

  18. Slide 18: IDA Phase 3 Top-line Results: Safety

    AE Category Ferric Citrate (N=117) % (n) Placebo (N=116) % (n) Most common AEs Diarrhea 20.5 (24) 16.4 (19) Constipation 18.8 (22) 12.9 (15) Discolored feces 14.5 (17) 0 Nausea 11.1 (13) 2.6 (3) SAEs 12.0 (14) 11.2 (13) AEs leading to discontinuation 10.3 (12) 8.6 (10) Death 1.7 (2) 0 The majority o

  19. Slide 19: Ferric Citrate Has Potential to Benefit Many More CKD Patients

    Ferric Citrate Has Potential to Benefit Many More Patients with Chronic Kidney Disease Anemia Management Registration Phase 3 study demonstrated statistically significant differences between the ferric citrate and placebo groups for the primary and all pre-specified secondary endpoints Plan to submi

  20. Slide 20: Closing Remarks & Q&A

    Closing Remarks & Q&A Greg Madison

  21. Slide 21: A Potential New Treatment Category for CKD

    A Potential New Treatment Category for CKD Phosphate Management Anemia Management Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; Ferric citrate is being evaluated for use in non-dialysis dependent CKD patients as a treatment for iron deficiency

  22. Slide 22: Priorities for the Future and Progress Toward Potential Auryxia Label Expansion

    Priorities for the Future and Progress Toward Potential Auryxia Label Expansion Drive Auryxia’s path to success in dialysis: Increase awareness Drive breadth and depth of prescribing Finalize Ph 3 IDA NDD-CKD trial and report top-line results Submit sNDA Begin potential IDA/NDD-CKD launch activities

  23. Slide 23: First Quarter 2016 Financial Results

    First Quarter 2016 Financial Results April 28, 2016 Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals — Q1 2016 Earnings Presentation on 6ix